Jon Napitupulu

Vaxcyte has launched a comprehensive phase 3 program for VAX-31, its 31-valent pneumococcal conjugate vaccine, with head-to-head noninferiority testing...

BridgeBio Pharma reported $154.2 million in fourth-quarter revenues and $502.1 million for full-year 2025, propelled by ATTRuby’s first full...

Myriad Genetics closed 2025 with flat fourth-quarter revenue at $209.8 million, a 70% gross margin, and a modest GAAP...

Telix Pharmaceuticals reported full-year 2025 revenue of US$803.8 million, up 56% year over year, and issued 2026 guidance of...

Amicus Therapeutics posted 2025 revenue of $634.2 million, up 20% reported and 17% at constant exchange rates, anchored by...

Galapagos has executed a strategic reset alongside its full-year 2025 results, moving to wind down its cell therapy business,...

TG Therapeutics will host its fourth-quarter and full-year 2025 results call on February 26, with a 2026 outlook that...

Recordati posted preliminary 2025 results that extend its run as one of Europe’s most profitable mid-cap pharmas: net revenue...

Psyence Biomedical secured shareholder approval to elect its slate of directors, appoint MNP LLP as auditor, and grant the...

Cue Biopharma reported new preclinical safety and tolerability data for CUE-401, its lead autoimmune candidate, from non-GLP mouse and...